Skip to content
10-Q

Quarterly Report

NUTRA PHARMA CORP. NPHC

0001493152-26-026420

← back to feed
Filed
May 29, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 29, 2026 7.16B sh
Shares Diluted Q1 2026 · Mar 31, 2026 8.01B sh
Shares Diluted Q1 2026 · Mar 31, 2025 7.68B sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$327.79K
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$405.01K
Long Term Debt Q1 2026 · Mar 31, 2026 $135.73K
Long Term Debt Q1 2026 · Dec 31, 2025 $136.64K
Short Term Investments Q1 2026 · Mar 31, 2026 $17.6K
Short Term Investments Q1 2026 · Dec 31, 2025 $17.6K
Stockholders Equity Q1 2026 · Mar 31, 2026 −$17.26M
Stockholders Equity Q1 2026 · Dec 31, 2025 −$16.83M
Stockholders Equity Q1 2026 · Mar 31, 2025 −$16.21M
Stockholders Equity Q1 2026 · Dec 31, 2024 −$14.81M
Current Liabilities Q1 2026 · Mar 31, 2026 $17.74M
Current Liabilities Q1 2026 · Dec 31, 2025 $17.27M
Total Liabilities Q1 2026 · Mar 31, 2026 $17.88M
Total Liabilities Q1 2026 · Dec 31, 2025 $17.41M
Current Assets Q1 2026 · Mar 31, 2026 $499.42K
Current Assets Q1 2026 · Dec 31, 2025 $459.58K
Total Assets Q1 2026 · Mar 31, 2026 $616.52K
Total Assets Q1 2026 · Dec 31, 2025 $584.56K
Eps Diluted Q1 2026 · Mar 31, 2026 $0.00
Eps Diluted Q1 2026 · Mar 31, 2025 $0.00
Eps Basic Q1 2026 · Mar 31, 2026 $0.00
Eps Basic Q1 2026 · Mar 31, 2025 $0.00
Net Income Q1 2026 · Mar 31, 2026 −$459.68K
Net Income Q1 2026 · Mar 31, 2025 −$1.4M
Operating Income Q1 2026 · Mar 31, 2026 −$379.25K
Operating Income Q1 2026 · Mar 31, 2025 −$349.82K
Gross Profit Q1 2026 · Mar 31, 2026 $18.98K
Gross Profit restated Q1 2026 · Mar 31, 2025 $59.13K
Revenue Q1 2026 · Mar 31, 2026 $27.25K
Revenue Q1 2026 · Mar 31, 2025 $73.97K
Capex Q1 2026 · Mar 31, 2025 $26.05K